




PATENT
ATTORNEY DOCKET NO. 50195/008003

Certificate of Mailing: Date of Deposit: January 28, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan M. Cannon

Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	James M. Robl et al.	Art Unit:	1632
Serial No.:	09/988,115	Examiner:	Deborah Crouch
Filed:	November 16, 2001	Customer No.:	21559
Title:	EXPRESSION OF XENOGENOUS (HUMAN) IMMUNOGLOBULINS IN CLONED, TRANSGENIC UNGULATES		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in


payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.

If there are any charges or any credits, please apply them to Deposit Account

No. 03-2095.

Respectfully submitted,

Date: 1/28/05



Karen D. Elbing, Ph.D.

Reg. No. 35,238

Michael T. Bellman, Ph.D.
Reg. No. 52,608

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

Sheet 1 of 2


SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50195/008003
	Serial No.	09/988,115
	Applicant	James M. Robl et al.
	Filing Date	November 16, 2001
	Group	1632
	IDS Filed	January 28, 2005
Customer No.	21559	

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 99/60108	11/25/1999	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Echelard et al., Cloned cattle engineered to carry an artificial chromosome encoding human immunoglobulin genes are a significant leap toward the production of safer and more potent therapeutic antibodies, <i>Nat. Biotechnol.</i> 20:881-882, 2002.
	Farrugia et al., Intravenous immunoglobulin: regulatory perspectives on use and supply, <i>Trans. Med.</i> 11:63-74, 2001.
	Fishwild et al., Highavidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice, <i>Nat. Biotech.</i> 14:845-851, 1996.
	Ishida et al., Production of human monoclonal and polyclonal antibodies in transchromo animals, <i>Clon. Stem Cells</i> 4:91-102, 2002.
	Joziase et al., Xenotransplantation: the importance of the Gal α 1,3Gal epitope in hyperacute vascular rejection, <i>Biochim. et BioPhys.</i> 1455:403-418, 1999.
	Kuroiwa et al., Cloned transchromosomal calves producing human immunoglobulin, <i>Nat. Biotech.</i> 20:889-894, 2002.
	Lonberg et al., Human antibodies from transgenic mice, <i>Intern. Rev. Immun.</i> 13:65-93, 1995.
	Lucier et al., Multiple sites of V λ diversification in cattle, <i>J. Immun.</i> 161:5438-5444, 1998.
	Mendez et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, <i>Nat. Genet.</i> 15:146-156, 1997.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

Sheet 2 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50195/008003
	Serial No.	09/988,115
	Applicant	James M. Robl et al.
	Filing Date	November 16, 2001
	Group	1632
	IDS Filed	January 28, 2005
Customer No.	21559	

	Raeber et al., Ectopic expression of prion protein (PrP) in T lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication, <i>Proc. Natl. Acad. Sci.</i> 96:3987-3992, 1999.
	Sandrin et al., Recent advances in xenotransplantation, <i>Curr. Opin. in Immun.</i> 11:527-531, 1999.
	Stiehm et al., Appropriate therapeutic use of immunoglobulin, <i>Trans. Med. Rev.</i> X:203-221, 1996.
	Tomizuka et al., Functional expression and germline transmission of a human chromosome fragment in chimaeric mice, <i>Nat. Genet.</i> 16:133-143, 1997.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	